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Edited by Angel NebredaAbstract Lysophosphatidic acid (LPA) is a phospholipid mes-
senger with diverse eﬀects mediated via receptors LPA1, LPA2
and LPA3. Our previous study revealed that serum LPA level
is elevated after myocardial infarction (MI). However, very little
is known about the eﬀects of LPA on cardiac ﬁbroblasts (CFs)
that play a crucial role in left ventricular remodeling after MI.
Here we demonstrated that LPA dose-dependently induced pro-
liferation and collagen synthesis with the maximum stimulation
at 10 lM that was preferentially mediated by LPA3. LPA also
dose-dependently induced apoptotic cell death, as estimated by
MTT assay, hoechst staining, TUNEL and ﬂow cytometric anal-
ysis, with an IC50 of 50 lM. Moreover, apoptotic cell death may
involve mitochondrial dysfunction and activation of caspase-3.
Apoptosis induced by LPA might be mediated by LPA1. These
data suggest that LPA exerts dual proliferative and proapoptotic
actions mediated by speciﬁc LPA receptor subtypes.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Lysophosphatidic acid (LPA) is a simple and natural
phospholipid with multiple functions promoting cell growth,
survival, diﬀerentiation, apoptosis and migration [1,2], largely
mediated through LPA1, LPA2 and LPA3 receptors, which
are known as G-protein coupled receptors. LPA receptors be-
long to endothelial diﬀerentiation genes (Edg) family formerly
named Edg2, Edg4, Edg7 [3]. We recently reported a signiﬁ-
cant elevation (maximal 6.3-fold) in serum LPA concentration
in patients with myocardial infarction (MI) [4], indicating a
role of LPA in cardiac pathophysiology. Indeed, several stud-
ies have reported cardiovascular actions of LPA. LPA may be
involved in process of angiogenesis and atherosclerosis [1,5], as
well as regulation of blood vessel tone [5]. In cultured neonatal
cardiomyocytes, LPA induces hypertrophy [6,7] and prevents
hypoxia-induced apoptosis [8]. In the process of left ventricular
(LV) remodeling, cardiac ﬁbroblasts (CFs), which constitute*Corresponding authors. Fax: +86 10 88396050.
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doi:10.1016/j.febslet.2006.07.06160% of the total heart cells, are known to play a pivotal role
in the pathologic structural changes by undergoing prolifera-
tion, deposition of extracellular matrix proteins such as colla-
gen, and replacing myocytes with ﬁbrotic scar [9,10]. However,
to our knowledge, there has been no investigation on the po-
tential of LPA on CFs. Here we have examined the eﬀects of
LPA on primary cultured neonatal CFs and the signaling path-
ways involved. We took advantage of recent development of
selective LPA receptor subtypes antagonists and agonists to
elucidate the biphasic eﬀects of LPA and role of LPA receptor
subtypes on primary cultured CFs.2. Materials and methods
2.1. Materials
LPA (oleoyl C: 18:1), OMPT (1-oleoyl-2-Omethyl-rac-glycero-phos-
phothionate), Hoechst 33342, Rhodamine 123, MTT (3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyl tetrazolium bromide) were obtained from
Sigma–Aldrich. DGPP [dioctylglycerol pyrophosphate (8:0)] was from
Avanti Polar Lipids. Dodecylphosphate, Z-DEVD-pNA, were prod-
ucts of Biomol Research Labs. Z-VAD-FMK and Z-DEVD-FMK
were form R& D systems. Primary antibodies were from Cell Signaling
Technology. Horseradish peroxidase-conjugated secondary antibodies
were from Santa Cruz Biotechnology.
2.2. Cell culture
Neonatal CFs were isolated from Sprague–Dawley rats (1–3 days
old) and characterized as we previously described [11]. Brieﬂy, neona-
tal hearts were dissected free of atria, minced and trypsinized at 37 C
with gentle stirring in HEPES buﬀered Saline A (in mM: 137 NaCl, 5.4
KCl, 4.2 NaHCO3, 5.5 glucose, 1.0 HEPES, pH 7.4) containing 0.1%
trypsin (Hyclone). Then cells were centrifuged, resuspended and plated
for 80 min in DMEM/F12 (Hyclone) containing 10% fetal bovine ser-
um (Gibco), 100 U/ml penicillin and 100 lg/ml streptomycin. During
this period of time, the CFs attached readily to the bottom of culture
dish while the cardiomyocytes remained ﬂoating, allowing for separa-
tion of the 2 populations. All experiments were performed in the sec-
ond and third passages after starvation in serum-free DMEM/F12
for 24 h. Thereafter, CFs were treated with various agents as indicated.
2.3. Preparation of RNA and RT-PCR analysis
CFs were cultured in complete medium or serum starvation and
stimulated with various concentrations of LPA on T25 ﬂask. Total
RNA was extracted from CFs grown to 90% conﬂuences using Trizol
reagent (Invitrogen) and quantiﬁed using ultraviolet (UV) spectropho-
tometer. Following the preparation of RNA, a reverse transcription
polymerase chain reaction (RT-PCR) analysis was performed as we
previously described [12]. Equal aliquots of reverse-transcribed RNA
were used to amplify the LPA receptor subtypes. For analysis of
expression of collagen I and collagen III, preliminary experiments were
carried out to determine the optimal conditions including number of
cycles and amount of cDNA required for ampliﬁcation over a linearblished by Elsevier B.V. All rights reserved.
Table 1
Description of the designed primers and reaction conditions for reverse transcription-polymerase chain reaction (RT-PCR)





LPA1 (386 bp) TCTTCTGGGCCATTTTCAA 95 C/30 s, 55 C/30 s, 72 C/45 s, 32 cycles
GCCGTTGGGGTTCTCGTT
LPA2 (488 bp) CCTACCTCTTCCTCATGTTC 95 C/30 s, 59 C/30 s, 72 C/45 s, 32 cycles
AATGATGACAACCGTCTTGACTA
LPA3 (437 bp) TGT CAACCGCTGGCTTCT 95 C/30 s, 62 C/30 s, 72 C/45 s, 32 cycles
CAGTCATCACCGTCTCATTAG
Collagen I (462 bp) TGC CGT GAC CTC AAG ATG TG 95 C/45 s, 56 C/45 s, 72 C/45 s, 32 cycles
CAC AAG CGT GCT GTA GGT GA
Collagen III (336 bp) CGA GGT GAC AGA GGT GAAAGA 95 C/45 s, 56 C/45 s, 72 C/45 s, 30 cycles
AAC CCA GTA TTC TCC GCT CTT
GAPDH (195 bp) CCATGGAGAAGGCTGGG 95 C/30 s, 56 C/30 s, 72 C/45 s, 25 cycles
CAAAGTTGTCATGGATGACC
4738 J. Chen et al. / FEBS Letters 580 (2006) 4737–4745range. PCR ampliﬁcation of the cDNA was performed using rTaq
DNA polymerase (Takara). GAPDH was used as an internal control
for equal loading of mRNA. The sequences of primers and reaction
conditions are depicted in Table 1. Each PCR product (10 ll) was
run on 1.5% agarose gels and bands were visualized with a UV trans-
illuminator (Bio-Rad) followed by computerized densitometric analy-
sis.
2.4. [3H] Thymidine, [3H] leucine and [3H] proline uptake assays
CFs were transferred to 24-well plates, starved of serum for 24 h,
and then stimulated with LPA or dodecylphosphate(a selective LPA2
agonist [13]), or OMPT (a selective LPA3 agonist [14]), at various con-
centrations for 48 h. DGPP which acts as an eﬀective antagonist for
LPA1 and LPA3 [15], was pre-incubated with cells for 1 h prior to
stimulation with LPA for 48 h in the serum-free medium. [3H] thymi-
dine or [3H] leucine (Institute of High Energy Physics, Chinese Acad-
emy of Sciences) was added to each well at a ﬁnal concentration of
1 lCi/ml, respectively, during the last 6 h of incubation. [3H] proline
(1 lCi/ml) was added to the plate 8 h after addition of LPA. Stimula-
tions were terminated by rinsing the CFs three times with PBS and
then adding ice-cold 10% TCA for 30 min. Cell precipitates were
washed three times with ice-cold PBS and then solubilized in 1%
SDS/0.1 M NaOH overnight at room temperature. Radioactivity of
SDS-soluble protein was determined by liquid scintillation spectrome-
try (Beckman, model LS6000-SC, USA).
2.5. Evaluation of viable cell number and mitochondrial function
The number of viable cells was measured using MTT assay which is
also an indicator of mitochondrial function [16]. CFs were seeded in
96-well plates as described above and incubated with diﬀerent reagents.
A stock solution of MTT was prepared in PBS, diluted in DMEM, and
added to each well at a ﬁnal concentration of 0.5 mg/ml after removal
of the culture medium. Then the cells were incubated at 37 C for 4 h.
The supernatants were removed from the wells, and 100 ll of DMSO
was added to each well to dissolve the blue formazan product. Quan-
titative colorimetric assay at 570 nm was measured on a 96-well scan-
ning spectrophotometer.
2.6. Assessment of morphological changes
CFs were examined using a phase-contrast microscope and digital
images were obtained. Nuclear condensation and fragmentation were
assayed using chromatin dye Hoechst 33342 [17]. Cells were washed
with PBS and stained by 5 lg/ml Hoechst 33342 before visualized using
ﬂuorescent microscopy. Apoptotic cells were characterized by morpho-
logical alteration as condensed nuclei and cell shrinkage.
2.7. TUNEL analysis
Cells were seeded on 22 mm glass coverslips in 6-well plates. After
treatment with diﬀerent concentration of LPA, CFs were washed with
PBS and ﬁxed with 4% paraformaldehyde in PBS (pH 7.4) for 30 minat room temperature. The ﬁxed cells were stained by the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) method, using an In Site Cell Death Detection Kit, AP
(Roche) according to the manufacturer’s instructions.
2.8. Flow cytometric analysis
Apoptosis was judged by DNA fragmentation as described previ-
ously [18]. Stimulated cells were harvested and washed twice with
Ca2+/Mg2+ free PBS, ﬁxed overnight in 70% cold ethanol, digested
with RNase A (Sigma) and stained with propidium iodide (PI) buﬀer
(0.1% Triton X-100, 0.1% trisodium citrate, and 100 lg/ml PI). After
incubation for 10 min, the degree of DNA fragmentation was mea-
sured and analyzed by ﬂow cytometry on FACSC- LSR (BD).
The loss of mitochondrial membrane potential (Dwm) was assessed
using Dwm-speciﬁc stain Rhodamine 123. In brief, after treatment with
various concentration of LPA, 105 cells were stained in a solution con-
taining 0.1 lM Rhodamine 123 for 30 min in 37 C. Staining was
quantiﬁed by scatter characteristic employing a ﬂow cytometer EPICS
XL from CouLTER (USA) with each sample containing 2 · 104 cells.
Each examination was performed in duplicates.
2.9. Protein extraction and Western blot analysis
Stimulated cells were rinsed twice with ice-cold PBS and then lysed
for 30 min with ice-cold lysis buﬀer (1% Triton X-100, 50 mM Tris (pH
7.5), 150 mM NaCl, 1 mM Na3VO4, 1 mM EDTA, 1 mM EGTA,
2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM
PMSF, 1 mg/ml each of leupeptin, aprotinin, and pepstatin). Protein
concentration was determined using a Coomassie brilliant blue
(CBB) G250 solution (0.1 g/l CBB G250, 4.75% ethanol and 8.5%
phosphatic acid). Protein extractions were then mixed with 5 · SDS
sample buﬀer and boiled for 5 min. Equal amount of protein per lane
was loaded and separated through 12% SDS–PAGE gels (Bio-Rad)
and then transferred (Semi-Dry Transfer Cell, Bio-Rad) to a nitrocel-
lulose membrane (Amersham). After blocking in 5% skimmed milk for
1 h, membranes were rinsed and incubated overnight at 4 C with di-
luted primary antibody in 5% BSA (Sigma), 1 · TBS, 0.1% Tween-20
(TBS/T), with gentle shaking. Excess antibody was then removed by
washing the membrane in TBS/T and subsequently incubated for 2 h
with HRP-conjugated secondary antibody at room temperature. After
several washes in TBS/T, bands were visualized with an enhanced
chemiluminescence detection kit (Santa Cruz) and exposed to radio-
graphic ﬁlm.2.10. Determination of caspase-3 activity
Caspase-3 activity was measured by using pNA-derived chromo-
genic substrates: Z-DEVD-pNA [17]. In brief, cells were lysed for
30 min on ice with a buﬀer containing 1% Triton X-100, 20 mM
HEPES (pH 7.5), 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, 1 mM PMSF, and 1 mg/ml each of leupeptin, aprotinin, and
pepstatin. Samples were then centrifuged at 14000 · g for 3 min. Pro-
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reaction buﬀer (100 mM HEPES, pH 7.6, 20% glycerol, 1 mM DTT,
and 0.1 mM EDTA), and 1 ll (ﬁnal concentration 100 lM) of
10 mM pNA peptide substrates. Samples were then incubated for an
additional 2 h at 37 C, and DEVD-pNA cleavage was estimated by
enzyme-catalyzed release of pNA that was determined with absorbance
at 405 nm in a microtiter plate reader.
2.11. Statistical analysis
Data are expressed as mean ± standard deviation (S.D.). Diﬀerences
among groups were tested by one-way ANOVA. Comparisons be-
tween two groups were evaluated using Student’s t test. A value of
P < 0.05 was considered as statistically signiﬁcant.3. Results
3.1. Eﬀect of LPA on DNA and protein syntheses of CFs
We determined whether LPA could induce CFs proliferation
by [3H] thymidine or [3H] leucine incorporation. As shown in
Fig. 1A, LPA dose-dependently increased DNA and protein
syntheses in CFs with serum-free medium for 48 h. The maxi-Fig. 1. Dose dependent LPA-induced CFs proliferation. Serum-starved cells
indicated concentrations. The incorporation of (A) [3H] thymidine, [3H] leucin
stimulated mRNA expression of collagen I (462 bp) and collagen III (336 bp)
to the levels of GAPDH (195 bp). Data are expressed as the mean ± S.D. *P
paper, similar results were obtained from at least three independent experimmum uptake of either [3H] thymidine (+150 ± 18% from con-
trol level) or [3H] leucine (+203 ± 15 % from control level)
occurred by LPA at 10 lM stimulation. Further increment of
LPA concentrations actually caused reduction in these param-
eters. Moreover, LPA enhanced collagenase-sensitive [3H] pro-
line incorporation, as well as mRNA expression of collagen I
and collagen III at lower concentrations (1–10 lM) of LPA
but not at higher concentrations (25–50 lM) (Fig. 1B and C).
3.2. LPA1/LPA3 receptor mediate LPA-induced CFs
proliferation
As a prelude to explore the signaling responses activated by
LPA, we performed the RT-PCR to determine expression of
subtypes of LPA receptor. As shown in Fig. 2A, the mRNA
of all LPA1, LPA2 and LPA3 were expressed in CFs.
As shown in Fig. 2B, LPA1/LPA3 antagonist DGPP (25–
100 lM) completely inhibited the uptake of [3H] thymidine
stimulated by LPA (5 lM). OMPT (LPA3 agonist) signiﬁ-
cantly stimulated DNA synthesis at 1–10 lM (Fig. 2D). Dode-
cylphosphate (LPA2 agonist) had no eﬀect on the increasedwere incubated in serum-free medium for 48 h with addition of LPA at
e, (B) [3H] proline was determined as described in Section 2. (C) LPA-
were tested by RT-PCR. The levels of diﬀerent bands were normalized
< 0.05, **P < 0.01 vs. control. For this and all other illustration in this
ents.
Fig. 2. Speciﬁc LPA receptor subtypes mediate the LPA-induced proliferation of CFs. (A) Expression of LPA receptors in CFs was tested by RT-
PCR with speciﬁc primers. CFs were treated for 48 h with (B) DGPP (50 lM), (C) dodecylphosphate (0.05–50 lM) or (D) OMPT (0.01–100 lM) in
the presence or absence of LPA (10 lM). The incorporation of [3H] thymidine in CFs was determined as detailed in Section 2. Data are expressed as
the mean ± S.D. **P < 0.01 vs. control; ##P < 0.01 vs. LPA alone.
4740 J. Chen et al. / FEBS Letters 580 (2006) 4737–4745[3H] thymidine incorporation at low concentration (0.05–
5 lM) but inhibited DNA synthesis at higher concentrations
(25–50 lM) (Fig. 2C).
3.3. LPA induces CFs apoptosis
Given that LPA increases [3H] thymidine and [3H] leucine
uptake, we next explored the eﬀect of LPA on viability of
CFs, estimated by MTT assay in serum-starved cells treated
with various concentrations of LPA. Unexpectedly, LPA
dose-dependently reduced the number of viable cells with an
IC50 of approximately 50 lM. As a positive control, addition
of 10% serum for 24, 48 and 72 h increased the number of via-
ble cells by 1.2-, 1.3- and 1.5-fold, respectively (Fig. 3A). To
further explore whether LPA induces apoptotic cell death in
CFs, we performed chromosomal condensation analysis with
Hoechst 33342 staining, TUNEL assay and ﬂow cytometric
analysis. As shown in Fig. 3B, most cells of control group
had regular nuclei morphology but these cells exposed to
LPA (25–50 lM) displayed chromatin condensation togetherwith the notable increase of DNA fragmentation from 15.5%
(control) to 66.8% at 25 lM and 69.8% at 50 lM, respectively.
Similarly, TUNEL assay also revealed increased TUNEL-po-
sitive cells by LPA in a dose-dependent manner with a maxi-
mal positive ratio of 24.1% at 100 lM (Fig. 3B and C).
These results suggest that LPA is proapoptotic to primary cul-
tured CFs.
3.4. Eﬀects of LPA on mitochondrial function and caspase-3
activity
Apoptosis may involve mitochondrial dysfunction. As
shown in Fig. 3A, the results of MTT assay indicated a
dose-dependent decrease of mitochondrial viability stimulated
by LPA. In addition to MTT assay, mitochondrial function
was also evaluated by the loss of Dwm in order to avoid inter-
ference of some cellular enzyme systems on MTT reduction.
We also observed that CFs exposure to LPA resulted in a
slight loss of Dwm at 5 lM and such eﬀect was sustained at
higher doses (25–50 lM) (Fig. 4A). These results suggest that
Fig. 3. LPA induced apoptotic cell death in CFs. (A) Serum-starved cells were incubated in serum-free medium with concentration gradient of LPA
for 24–72 h. Serum-treated cells as positive control. MTT assay was used as a measure for the number of viable cells. Data are expressed as the
mean ± S.D. *P < 0.05 **P < 0.01 vs. respective control. (B) Apoptotic cell death was detected by Hoechst 33342 for staining chromosomal
condensation (top), TUNEL analysis (middle), and ﬂow cytometric analysis for DNA fragmentation (bottom). (C) LPA dose-dependently increased
TUNEL positive cells by using In Site Cell Death Detection Kit.
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apoptotic process, notably at higher concentrations (25–
50 lM).
We next tested the ability of LPA to induce caspase-3 activa-
tion. LPA induced a dose-dependent cleavage of the 35-kDa
pro-caspase-3, resulting in the appearance of the 19-kDa active
form of this caspase (Fig. 4B). Moreover, the direct measure-
ment of caspase-3 activity was exerted with the substrate
DEVD. The proteolytic cleavage of Z-DEVD-pNA yields a
signal that can be used to assess caspase-3 activity. As show
in Fig. 4C, LPA (25 lM) increased caspase-3 activity with
the maximal eﬀect occurring within 12 h (Fig. 4C). To deter-
mine the functional importance of caspase activation in
LPA-induced CFs apoptosis, we used Z-VAD-FMK, a general
caspase inhibitor and Z-DEVD-FMK, a caspase-3-speciﬁc
inhibitor. Both Z-VAD-FMK (100 lM) and Z-DEVD-FMK
(100 lM) signiﬁcantly blocked CFs death induced by LPA
(25 and 50 lM), as evident from MTT assay (Fig. 4D). These
data indicate that LPA induces cell death via the caspase-3
dependent pathway.
3.5. Speciﬁc receptor subtype mediates LPA-induced cell death
To explore which LPA receptor subtype actually mediated
the LPA-induced cell death, DGPP (speciﬁc LPA1/3 antago-
nist), dodecylphosphate (LPA2 agonist) and OMPT (LPA3
agonist) were used. Dodecylphosphate (0.5–50 lM) and
OMPT (0.01–50 lM) alone did not induce cell death. Dodecyl-
phosphate at 5 or 10 lM, or OMPT at 1 lM, statistically in-
creased the number of viable cells estimated by MTT
analysis (Fig. 5A and B). DGPP (50 lM) abolished CFs death
by LPA at 25lM (Fig. 5 C). Moreover, ﬂow cytometric anal-
ysis of DNA fragmentation revealed that DGPP (50 lM) pre-
vented LPA (25 lM)-induced increase of DNA content (M1)
from 47.2% to 24.3% while dodecylphosphate (50 lM) and
OMPT (1 lM) showed a marginal eﬀect on CFs. Morpholog-
ical analyses also led to the similar conclusions (Fig. 5D). Col-
lectively, these data suggest that LPA1 is likely involved in
LPA-induced cell death whilst LPA2 and LPA3 are less impor-
tant.Fig. 4. Mitochondrial dysfunction and caspase activity in CFs exposed
to LPA. (A) Changes in Dwm detected by ﬂow cytometry of
Rhodamine 123-stained cells. Serum-starved CFs were incubated
without or with LPA at 5, 25, 50 lM for 48 h. Analysis for (B)
procaspase-3 cleavage detected by immunoblotting and (C) caspase-3
activity determined by colorimetric assay. (D) Cells were incubated
with caspase3 inhibitor Z-DEVD-FMK (100 lM) and general caspase
inhibitor Z-VAD-FMK (100lM) for 1 h before LPA treatment for
48 h. The number of viable cells was test by MTT assay. Data are
expressed as the mean ± S.D. **P < 0.01 vs. 25lM LPA treatment;
##P < 0.01 vs. 50 lM LPA treatment.4. Discussion
LPA is constitutively present in serum at physiological con-
centrations of 2–20 lM [19]. Under pathological conditions,
LPA is released to serum from platelets in response to injury
and thrombosis [20,21] as well as to MI as our previous report
that the maximal elevation of serum LPA level is up to 6.3-fold
[4]. In this study, by using 0.1–100 lM LPA, covering the
physiological and pathological LPA concentrations in vivo,
we demonstrate for the ﬁrst time that, LPA exerts dual prolif-
erative and proapoptotic actions on CFs due to distinct func-
tion of subtypes of LPA receptors.
A large body of evidence suggests that LPA induces cell
growth in various cell types [22,23]. In agreement with these re-
sults, our data revealed that LPA induces incorporations of
[3H] thymidine and [3H] leucine in a dose-dependent manner.
Moreover, LPA stimulates the synthesis of collagen I and col-
lagen III. What was unexpected to us was the results from
MTT assays showing that instead of promoting CFs prolifer-
ation, LPA remarkably decreased the number of viable cells,
a novel action by LPA on CFs. We further veriﬁed that
Fig. 5. Speciﬁc LPA receptor subtypes mediate the LPA-induced apoptotic cell death in CFs. Cells were treated for 48 h with (A) dodecylphosphate
(0.05–50 lM), (B) OMPT(0.01–50 lM)or (C) DGPP (50 lM) in the presence or absence of LPA (25 lM). MTT assay was performed as described in
Section 2. Data are expressed as the mean ± S.D. **P < 0.01 vs. control; ##P < 0.01 vs. LPA alone. (D) Cells were treated for 48 h with
dodecylphosphate (50 lM), OMPT (1 lM) or DGPP (50 lM) in the presence or absence of LPA (25 lM). Phase contrast images and ﬂow cytometric
analysis are shown in the upper and lower panels, respectively.
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apoptotic cell death as conﬁrmed by TUNEL assay, Hoechst
33342 staining and ﬂow cytometric analysis. In addition to
being crucial for energy production, mitochondria are also
known to act as key regulators of apoptosis in several cell types
[24]. The conversion of MTT to its reduced form, a reaction
mediated by mitochondrial reductases, was used as index of
mitochondrial viability. Our data from MTT assay indicated
that LPA signiﬁcantly decreased the mitochondrial viability.
In the light of the changes in mitochondrial function, the nota-ble loss of the mitochondrial membrane potential was also ob-
served. Furthermore, mitochondrial dysfunction followed by
activation of caspase-3, an executor of apoptosis, suggests that
mitochondria-dependent apoptotic pathway is involved in
LPA-induced cell death in CFs.
Considerable data supports that LPA contributes to its
mitogenic activity as a growth factor [22,23]. Nevertheless,
our data strongly indicates that LPA induces apoptotic cell
death in primary cultured CFs. It appears that LPA-induced
cell death is dependent on cell types. For instance, LPA in-
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27] although LPA promotes proliferation or survival in many
other cell types such as 3T3 ﬁbroblasts, Rat1/c-myc, Schwann
and Hela cells [28,29]. Moreover, increasing evidences showed
that LPA also exerts biphasic eﬀects between mitogenic and
proapoptotic responses in the same cell type, such as in T lym-
phoblastoma cells [30] and in cortical neurons [31] and the
eﬀects in kidney ischemia–reperfusion (I/R) injury [32]. LPA
elicits protective response at a low concentration but initiates
apoptosis at a higher concentration. In addition, in skeletal
muscle cells, the same concentration of LPA activated mito-
genic and apoptotic signaling pathway simultaneously
although there is no apparent increase of cellular viability or
death [33].
The multiple LPA receptor subtypes and diverse down-
stream signaling pathways may explain for the paradoxical
properties of LPA, as we observed on cell proliferation and
death. In the present study, the speciﬁc LPA3 agonist OMPT
promoted DNA synthesis and increased the living cells without
obvious evidence for apoptosis induction. Whereas the speciﬁc
LPA2 agonist, dodecylphosphate did not promote [3H] thymi-
dine uptake at a broad range of concentrations tested, it signif-
icantly inhibited the [3H] thymidine incorporation at doses of
25–50 lM without induction of apoptotic cell death. In com-
parison, the selective LPA1/3 antagonist DGPP abolished
the LPA-induced eﬀects of proliferation and apoptotic cell
death in CFs. Given that LPA3 preferentially mediates the
proliferation without induction of apoptosis and that LPA2
does not induce cell death but inhibited proliferation at higher
concentrations, we therefore considered that it is the LPA1
receptor that mediates the LPA-induced apoptosis and might
also be involved in proliferation induced by LPA. However,
since no speciﬁc LPA1 antagonist or agonist being available,
these conclusions remain to be validated by further study with
speciﬁc intervention on LPA1 under our experimental condi-
tions. In a recent study, overexpression of LPA1 was found
to induce apoptosis in multiple cell lineages including ovarian
cancer cell lines and T lymphocytes and LPA1 may serve as a
negative growth regulator [34]. In a model of renal I/R injury,
LPA2 was found to contribute to protective eﬀect whereas
LPA3 facilitated I/R injury [32]. Therefore, it seems that diﬀer-
ent LPA receptor subtypes mediate distinct functions of LPA
governing cell growth and other cell functions such as cancer
migration [35,36] or diﬀerentiation [1]. Cellular growth and
apoptosis are normally at a balanced state that is likely dis-
turbed under pathological conditions. LPA may therefore reg-
ulate the balance through binding to diﬀerent receptor
subtypes which mediate the opposite eﬀects. The diﬀerence in
the aﬃnity of LPA receptor subtypes may be responsible in
part for the opposite eﬀects induced by LPA at diﬀerent con-
centrations. The balance inclined to proliferation at low con-
centrations of LPA through LPA3 receptor (also likely to
activate LPA1) indicated by the ﬁnding that LPA at 10 lM in-
duced the maximal DNA and protein synthesis whilst only a
marginal increase in apoptosis was observed. At concentra-
tions higher than 25 lM, LPA predominantly induced apopto-
tic cell death mediated by LPA1 receptor although alive cells
still showed an increased DNA synthesis.
Moreover, abnormally increased level of LPA together with
temporally and spatially selective expression of subtypes of
LPA receptors under diseased conditions may also account
for the diverse bioactivities of LPA [2]. LV remodeling afterMI has been well known to involve a variety of cytokines sig-
naling. We have recently demonstrated a signiﬁcantly elevated
serum levels of LPA in patients after acute MI [4]. In addition,
in rat acute MI model, LPA3 receptor selectively expresses in
early phase of LV remodeling while expressions of LPA1
and LPA3 are both signiﬁcantly increased at a late phase
(our unpublished observations). In cultured neonatal cardio-
myocytes, LPA was found to protect cells from hypoxia-in-
duced apoptosis [8] and to promote hypertrophic growth [6].
Thus, there is good evidence for a role of LPA in the process
of LV remodeling. In the present study, we have generated re-
sults for the ﬁrst time suggesting the eﬀects of LPA on CFs, a
key cell population that contribute to LV remodeling leading
to heart failure.
Considering that LPA have dual eﬀects on CFs besides
induction of collagen synthesis in vitro that is critical to LV
remodeling, we proposed that LPA functions as a double-
edged sword through diﬀerent receptor subtypes in the myo-
cardial remodeling under pathological conditions. LPA seems
to promote predominantly proliferation of CFs and collagen
synthesis through activation of LPA3. In the contrary, activa-
tion of LPA1 by LPA might induce CFs death and inhibit col-
lagen synthesis, eﬀects that might have diverse impact on
myocardial remodeling pending on the stages of the disease.
Considering these features of LPA and diverse eﬀects mediated
by subtypes of LPA receptors, development of speciﬁc agonists
and antagonists might form a novel therapeutic strategy for
heart disease targeting LPA pathway. Therefore, further stud-
ies, including the use of in vivo models, are warranted to test
these possibilities.
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